
Celltrion Wins Brazil Cancer Drug Tender for Seventh Straight Year
Celltrion has secured a tender for its cancer treatment Herzuma in Brazil for the seventh consecutive year.
Celltrion has secured a tender for its cancer treatment Herzuma in Brazil for the seventh consecutive year.
Celltrion, a leading biopharmaceutical company, has announced its successful bid for a tender from the Brazilian federal government for its cancer treatment, Herzuma. This marks the seventh consecutive year that Celltrion has won this tender, reinforcing its strong foothold in the Brazilian market.
Herzuma, a biosimilar to Roche's Herceptin, is used for treating breast and stomach cancers. The drug has captured a significant 50% market share in Brazil, showcasing its effectiveness and acceptance among healthcare providers.
As part of the agreement, Celltrion will supply 1 million vials of Herzuma to the Brazilian government through next year. The Brazilian pharmaceutical market is largely public, with the federal government overseeing about 80% of it, which highlights the importance of this tender win for Celltrion.
Kang Gyeong-du, Celltrion's head for Latin America, expressed optimism about the company's future in the region, stating, "We will expand our footprint in Latin America with follow-up products." This strategic move is expected to further enhance Celltrion's presence in the competitive Latin American market.
Related companies
Where it matters
Related coverage

Celltrion Pharm Reports Increased Q3 Profit Driven by Higher Revenues
Samsung Biologics Completes 2.7 Trillion Won Rights Offering

Celltrion Launches Three New Biosimilars in Brazil
